Reddit Inc vs TG Therapeutics Inc — how do they compare? Reddit Inc trades at $159.84 (market cap $30.10B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: Reddit Inc is far larger — about 3.7× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Reddit Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Reddit Inc for 26 Days and TG Therapeutics Inc for 16 Days on average.
| RDDT | TGTX | |
|---|---|---|
Market Cap | $30.10B | $8.16B |
Volume | 4,560,440 | 1,735,121 |
Sector | Media | Health |
52-Week High | $258.93 | $59.06 |
52-Week Low | $121.84 | $26.94 |
Typical Hold Time | 26 Days | 16 Days |
Enterprise Value | $27.34B | $8.37B |
Signals from Pluang's Aura AI — not financial advice
Reddit (RDDT) trades at $159.84, up 4.63% today, showing strong momentum after three consecutive quarterly earnings beats. The stock maintains a bullish technical outlook with support at $154 and resistance at $160. Fundamentally, the company demonstrates exceptional profitability with 91.44% gross margins and 31.35% net income margins, while revenue growth accelerated to $2.8 billion in 2026. Recent developments include a strategic partnership with Zefr for AI-powered advertising solutions and expanding international revenues by 84%.
The investment outlook remains positive with 65.5% analyst buy ratings and a $202.52 consensus price target representing 27% upside potential. Key opportunities include continued AI data licensing growth and international expansion, while risks involve competitive pressure from Meta and regulatory concerns. The stock's premium valuation at 36.4x P/E requires sustained execution to justify current levels.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Reddit Inc. operates a vast network of online communities organized around various interests, known as 'subreddits'. Functioning as a hybrid of a social media platform and a discussion forum, the company generates revenue primarily through advertising and premium subscriptions. Reddit is a major hub for user-generated content, trending news, and viral discussions, and it is a key player in the digital advertising and social media landscape.
Read more on RDDT →TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →